References and Notes
1 Current Address: Cancer Research Lab. Hanno Advanced Research Lab., Taiho Pharmaceutical Co., Ltd. 1-27, Misugidai, Hanno-shi, Saitama, 357-8527, Japan.
2 Current Address: Fukaya Plant Tokyo Kasei Kogyo Co., LTD. 725 Kashiai Fukaya-shi, Saitama 366-0816, Japan.
3a
Yang CS.
Chung JY.
Yang G.
Chhabra SK.
Lee MJ.
J. Nutr.
2000.
130:
p.472S
3b
Tosetti F.
Ferrari N.
De Flora S.
Albini A.
FASEB J.
2002,
16:
2
4a
Nam S.
Smith DM.
Dou QP.
J. Biol. Chem.
2001,
276:
13322
4b
Smith DM.
Daniel KG.
Wang Z.
Guida WC.
Chan TH.
Dou QP.
Proteins: Struct. Funct. Bioinform.
2004,
54:
58
4c
Jankun J.
Selman SH.
Swiercz R.
Skrzypczak-Jankun E.
Nature
1997,
387:
561
4d
Sachinidis A.
Hescheler J.
Drug News Perspect.
2002,
15:
432
5a
Rensburg H.
Heerden PS.
Ferreira D.
J. Chem. Soc., Perkin Trans. 1
1997,
3415
5b
Jew S.-S.
Lim D.-y.
Bae S.-y.
Kim H.-a.
Kim J.-h.
Lee J.
Park H.-g.
Tetrahedron: Asymmetry
2002,
13:
715
5c
Nay B.
Arnaudinaud V.
Peyrat JF.
Nuhrich A.
Deffieux G.
Merillon JM.
Vercauteren J.
Eur. J. Org. Chem.
2000,
1279
5d
Zaveri NT.
Org. Lett.
2001,
3:
843
6a
Li L.
Chan TH.
Org. Lett.
2001,
3:
739
6b
Anderson JC.
Headley C.
Stapleton PD.
Taylor PW.
Tetrahedron
2005,
61:
7703
7
Miles CO.
Main L.
Nicholson BK.
Aust. J. Chem.
1989,
42:
1103
8
Murray RW.
Jeyaram R.
J. Org. Chem.
1985,
50:
2847
9a
Kaus GA.
Molina T.
Walling JA.
J. Chem. Soc., Chem. Commun.
1986,
1568
9b
Luengo JI.
Konialian-Beck A.
Rozamus LW.
Holt DA.
J. Org. Chem.
1994,
59:
6512
10 Procedure for the reductive cyclization to give (2R*,3R*)-3,4-dihydro-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-2H-chromen-3-yl 3,4,5-trimethoxybenzoate (14a): To a stirred solution of 2a (17 mg, 0.024 mmol) in CH2Cl2 (0.5 mL) was added a solution of triethylsilane (10%) and trifluoroacetic acid (25%) in CH2Cl2 at 0 °C. The reaction mixture was then warmed to r.t. for 4 h. Toluene (5 mL) was added to the reaction mixture and the volatile components were removed by evaporation in vacuo. The product was purified using column chromatography on silica gel, eluting with hexane-EtOAc (5:1 → 2:1) to afford 2a (12 mg, 0.021 mmol, 88%) as a white solid; mp 155-157 °C; IR (solid) 2940, 2839, 1717, 1621, 1592 cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.17 (s, 2 H), 6.70 (s, 2 H), 6.25 (d, J = 1.9 Hz, 1 H), 6.12 (d, J = 1.9 Hz, 1 H), 5.67 (m, 1 H), 5.09 (s, 1 H), 3.86 (s, 3 H), 3.81 (s, 6 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.72 (s, 6 H), 3.05 (d, J = 3.4 Hz, 2 H); 13C NMR (100 MHz, CDCl3): δ = 165.1, 159.7, 158.8, 155.5, 153.1, 152.8, 142.5, 137.9, 133.3, 125.1, 107.2, 103.9, 100.1, 93.2, 91.9, 77.7, 68.6, 60.9, 60.8, 56.2, 56.0, 55.4, 25.9.
11
(±)-Epigallocatechin gallate(1): mp 220 °C (dec); 1H NMR [400 MHz, acetone-d
6-D2O (2:1)]: δ = 6.89 (s, 2 H), 6.53 (s, 2 H), 5.90 (d, J = 2.4 Hz, 1 H), 5.89 (d, J = 2.4 Hz, 1 H), 4.89 (s, 1 H), 5.28 (s, 1 H), 2.87 (dd, J = 17.5, 4.4 Hz, 1 H), 2.78 (dd, J = 17.5, 1.6 Hz, 1 H); 13C NMR [100 MHz, acetone-d
6-D2O (2:1)]: δ = 212.2, 167.2, 157.3, 156.8, 146.2, 145.9, 139.3, 133.1, 130.6, 121.3, 110.2, 106.8, 98.9, 96.6, 95.7, 78.1, 70.3, 26.6. The analytical data (1H and 13C NMR) of 1 was identical to the commercially available authentic sample [(-)-EGCG, Wako Pure Chemical industries, Ltd.].